Spironolactone and gastrointestinal bleeding: A population based study

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 5, 2008, Pages 495-500

  Russo, Antonio ^a   Autelitano, Mariarjgela ^a   Bisanti, Luigi ^a  

^a Local Health Authority   (Italy)

Author keywords

Drugs adverse effects; Gastrointestinal bleeding; Propensity score; Spironolactone

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; CORTICOSTEROID; DIURETIC AGENT; IMMUNOMODULATING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DRUG EXPOSURE; DRUG MEGADOSE; DRUG USE; FEMALE; HAZARD RATIO; HOSPITAL ADMISSION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SCORING SYSTEM; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; UPPER GASTROINTESTINAL BLEEDING;

AGED; AGED, 80 AND OVER; BIAS (EPIDEMIOLOGY); COHORT STUDIES; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMANS; INCIDENCE; ITALY; MALE; MIDDLE AGED; PEPTIC ULCER; PILOT PROJECTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; SPIRONOLACTONE;

EID: 44249101861     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1583     Document Type: Article

References (12)

1. Pitt B, Zannad F, Remme WJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure, Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10): 709-717.
2. Baliga RR, Ranganna P, Pitt B, Koelling TM. Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis. J Card Fail 2006; 12(4): 250-256.
3. Williams EM, Katholi RE, Karambelas MR. Use and side-effect profile of spironolactone in a private cardiologist's practice. Clin Cardiol 2006; 29(4): 149-153.
4. Mackay A, Stevenson RD. Gastric ulceration induced by spironolactone. Lancet 1977; 1(8009): 481.
5. Kremer D, Fraser R, Brown JJ, Lever AF, Davies DL, Robertson JI. Amiloride in primary hyperaldosteronism with chronic peptic ulceration. Br Med J 1973; 2: 216-217.
6. Doll R, Langman MJ, Shawdon HH. Treatment of gastric ulcer with carbenoxolone: antagonistic effect of spironolactone. Gut 1968; 9: 42-45.
7. Reed PI, Lewis SI, Vincent-Brown A. The influence of amiloride on the therapeutic and metabolic effects of carbenoxolone in patients with gastric ulcer. A double-blind controlled trial. Scand J Gastroenterol Suppl 1980; 65: 51-57,
8. Slight SH, Chilakamarri VK, Nasr S. Inhibition of tissue repair by spironolactone: role of mineralocorticoids in fibrous tissue formation. Mol Cell Biochem 1998; 189: 47-54.
9. Verhamme K, Mosis G, Dieleman J, Stricker B, Sturkenboom M. Spironolactone and risk of upper gastrointestinal events: population based case-control study. Br Med J 2006; 333: 330-333.
10. Elixhauser A, Steiner C, Harris DR. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8-27.
11. D'Agostino RB, Jr. Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
12. Juurlink DN, Mamdani MM, Lee DS. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551.